Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Archie Meeties who wrote (6052)	3/27/2002 5:54:07 PM
From: Biomaven	Respond to of 52153

Thanks, Archimedes. There are a number of patients that currently receive home infusions of dobutamine/Milrinone. These are the obvious candidates for home use of Natrecor, and on a recent CC the company (or maybe a doctor they invited along) did talk about the potential for weekly home infusions for some patients. This link (from 1998) discusses home infusion of inotropes (principally Milrinone): amcp.org If you are correct that Natrecor will rapidly replace both Milrinone and dobutamine in acute CHF, then SCIO is definitely a buy at these levels. Peter